EN | RU
EN | RU

Help Support

Back

Safety and efficacy of pemafibrate in people having non-alcoholic fatty liver disease

Safety and efficacy of pemafibrate in people having non-alcoholic fatty liver disease Safety and efficacy of pemafibrate in people having non-alcoholic fatty liver disease
Safety and efficacy of pemafibrate in people having non-alcoholic fatty liver disease Safety and efficacy of pemafibrate in people having non-alcoholic fatty liver disease

This study was carried out to determine the safety and efficacy of pemafibrate (novel, selective peroxisome proliferator-activated receptor α modulator [SPPARMα]) in adults suffering from high-risk, non-alcoholic fatty liver disease (NAFLD).

See All

Key take away

In NAFLD people, pemafibrate therapy for 72 weeks did not decrease the liver fat content. But, it considerably reduced magnetic resonance elastography-based liver stiffness.

Background

This study was carried out to determine the safety and efficacy of pemafibrate (novel, selective peroxisome proliferator-activated receptor α modulator [SPPARMα]) in adults suffering from high-risk, non-alcoholic fatty liver disease (NAFLD).

Method

Overall, 118 participants were randomized to either 0.2 mg pemafibrate (n=58) or placebo (n=60), orally, twice daily for seventy-two weeks. In this randomized, placebo-controlled, double-blind, multicentre, phase 2 clinical trial, the key inclusion criteria included liver fat content of ≥10% by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF); liver stiffness of ≥2.5 kPa, by magnetic resonance elastography; and elevated alanine aminotransferase (ALT) levels.

The percentage alteration in MRI-PDFF from baseline to week 24 was the major outcome ascertained while magnetic resonance elastography-based liver stiffness, ALT, serum liver fibrosis markers and lipid parameters were the secondary outcomes ascertained.

Result

In terms of the primary outcome, no profound differences were noted between pemafibrate or placebo groups (treatment difference -1.0%), as shown in Table 1:


But, magnetic resonance elastography-based liver stiffness considerably dropped in comparison with placebo at week 48 (treatment difference -5.7%) and was maintained at week 72 (treatment difference -6.2%), with a considerable decline in ALT and low-density lipoprotein-cholesterol. Both the groups displayed comparable adverse events. The therapy was well-tolerated.

Conclusion

Pemafibrate appears to be a promising agent for NAFLD/non-alcoholic steatohepatitis, and also a candidate for combination therapy with agents that minimize fat content in the liver.

Source:

Alimentary Pharmacology & Therapeutics

Article:

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease

Authors:

Atsushi Nakajima et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: